2[ 18 F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography is a Sensitive Tool for the Detection of Occult Primary Cancer (Carcinoma of Unknown Primary Syndrome) with Head and Neck Lymph Node Manifestation

Abstract

BACKGROUND: The neck lymph nodes are a common site of metastases from carcinoma of unknown primary (CUP syndrome). 2[ 18 F]-fluoro-2-deoxy-D-glucose positron emission tomography (18-FDG-PET) has been shown to be a sensitive tool for detecting primary malignant lesions as well as metastatic spread. We have prospectively investigated the sensitivity of 18-FDG-PET in detecting occult primary carcinomas with manifestation in the head and neck lymph nodes.

METHODS: From May 1994 to July 1998, in 723 patients a cancer of the head and neck was diagnosed at the University of Cologne ENT outpatient clinic. The routinely performed staging procedures were chest radiography; full blood count; cervical and liver ultrasound; endoscopy of the nasopharynx, oropharynx, hypopharynx, larynx, and esophagus; and laboratory analyses. After the staging workup, in 27 of 723 patients (3.7%) CUP syndrome had to be presumed because the primary cancer could not be detected. In these patients 18-FDG-PET was performed, and images were reconstructed with a transmission-emission fusion technique.

RESULTS: In 7 of 27 patients (26%) 18-FDG-PET revealed an unknown primary: in 2 a bronchial carcinoma, in 2 a nasopharyngeal carcinoma, in 1 a squamous cell carcinoma of the parotid gland, in 1 a squamous cell carcinoma of the hypopharynx, and in 1 a carcinoma of the tonsil. In 4 of 7 patients the occult primary tumor was removed surgically. In 8 of 27 patients therapeutic strategy was changed as a result of the 18-FDG-PET findings.

CONCLUSION: 18-FDG-PET should be performed in all patients with CUP syndrome after conventional diagnostic workup fails to identify the primary.

Get full access to this article

View all access options for this article.

References

Abbruzzese

Hess

Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12:1272–80.

Muir

Cancer of unknown primary site. Cancer 1995; 75:353–6.

Jungehülsing

Eckel

Staar

Diagnosis and therapy of occult primary tumor with lymph node metastases in the area of the head and neck [in German]. HNO 1997; 45:573–83.

Abrams

Spiro

Goldstein

Metastases in carcinoma. Analysis of 1000 autopsied cases. Cancer 1950; 3:120–4.

Mackay

Ordonez

Ng.

Pathological evaluation of neoplasms with unknown primary tumor site. Semin Oncol 1993; 20:206–28.

Abbruzzese

Lenzi

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13:2094–103.

Subramanian

Chilla

Halsymphknotenmetastasen bei unbekanntem Primartumor. Verlaufsbeobachtung an 58 Patienten [Cervical lymph node metastases in unknown primary tumor. Follow-up of 58 patients]. HNO 1995; 43:299–303.

Leskinen

Lapela

Lindholm

Metabolic imaging by positron emission tomography in oncology. Ann Med 1997; 29:271–4.

Hawkins

Hoh

Ck.

PET FDG studies in oncology. Nucl Med Biol 1994; 21:739–47.

10.

Byers

Rm.

Neck dissection: Concepts, controversies, and technique. Semin Surg Oncol 1991; 7:9–13.

11.

Lefebvre

Coche-Dequeant

Van

Cervical lymph nodes from an unknown primary tumor in 190 patients. Am J Surg 1990; 160:443–6.

12.

Hamacher

Coenen

Stöcklin

Efficient stereospecific synthesis of non-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235–8.

13.

Pietrzyk

Herholz

Schuster

Clinical applications of registration and fusion of multimodality brain images from PET, SPECT, CT, and MRI. Eur J Radiol 1996; 21:174–82.

14.

Medina

Je.

A rational classification of neck dissections. Otolaryngol Head Neck Surg 1989; 100:169–76.

15.

Keyes

Jr Watson

Jr Williams

3rd

FDG PET in head and neck cancer. AJR Am J Roentgenol 1997; 169:1663–9.

16.

Bailet

Abemayor

Jabour

Positron emission tomography: A new, precise imaging modality for the detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992; 102:281–8.

17.

Jabour

Choy

Hoh

Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993; 186:27–35.

18.

Braams

Pruim

Freling

Mjm.

Detection of lymph node metastases of squamous cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995; 36:211–6.

19.

Greven

Williams

3rd Keyes

Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer?

Cancer J Sci Am 1997; 3:353–7.

20.

Haberkorn

Strauss

Reisser

Positron emission tomography (PET) in the evaluation of tumor proliferation and follow-up of therapy in ear, nose and throat tumors [in German]. Radiologe 1992; 32:296–301.

21.

Hoh

Dahlbom

Hawkins

Basic principles of positron emission tomography in oncology: Quantitation and whole body techniques. Wien Klin Wochenschr 1994; 106:496–504.

22.

Wahl

Cody

Hutchins

Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179:765–70.

23.

Braams

Pruim

Kole

Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997; 26:112–5.

24.

Kole

Nieweg

Pruim

Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82:1160–6.

25.

Schipper

Schrader

Arweiler

Positron emission tomography for primary tumor detection in lymph node metastases with unknown primary tumor [in German]. HNO 1996; 44:254–7.

26.

Abbruzzese

Raber

Frost

An effective strategy for the evaluation of unknown primary tumors. Cancer Bull 1988; 41:157–61.

27.

Wang

Goepfert

Barber

Unknown primary squamous cell carcinoma metastatic to the neck. Arch Otolaryngol Head Neck Surg 1990; 116:1388–93.

28.

Abbuzzese

Lenzi

Raber

The biology of unknown primary tumors. Semin Oncol 1993; 20:238–43.

29.

Frost

Levin

Clinical implications of metastatic process. Lancet 1992; 339:1458–61.

30.

Frost

Unknown primary tumors: An example of accelerated (type 2) tumor progression. Basic Life Sci 1991; 57:233–7.

31.

Knobber

Lobeck

Steinkamp

Hj.

Gibt es die malignisierte laterale Halszyste doch? [Does malignant lateral cervical cyst still exist?]

HNO 1995; 43:104–7.

32.

Devine

Kd.

Cancer in the neck without obvious source. Mayo Clin Proc 1978; 53:644–9.

33.

Ridenhour

Yeun

Spratt

Js.

Metastatic carcinoma in cervical lymph nodes from occult primary sites. A review. Mo Med 1967; 64:988–93.

34.

Kole

Nieweg

Pruim

Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82:1160–6.

35.

Adler

Faulhaber

Schnur

Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 1997; 203:323–7.

36.

Scott

Gobar

Hauser

Detection of scalene lymph node metastases from lung cancer. Positron emission tomography published erratum appears in Chest 1995; 107:1776. Chest 1995; 107:1174–6.